Mendel Biosciences Develops Al-Driven Software to Transform the Future of Healthcare

Mendel Biosciences, the Mexico-based biotech startup unveils pioneering AI software designed to accelerate drug development and reshape disease diagnostics.



Guadalajara, Jalisco May 7, 2025 (<u>Issuewire.com</u>) - Mendel Biosciences, a biotech company led by Mexican entrepreneur Raul Meza, is pioneering the development of a revolutionary Al-powered software aimed at transforming drug discovery, diagnostics, and personalized medicine. With a mission to accelerate medical research and reduce the time and cost of treatment development, Mendel is

introducing innovation to a healthcare system that is increasingly in need of speed, precision, and accessibility.

The software under development by Mendel Biosciences uses artificial intelligence to analyze cellular, molecular, and genomic data in order to identify disease markers, recommend personalized treatments, and predict the efficacy of drug compounds. This approach has the potential to shorten the drug discovery process from years to months while enabling precision in diagnostics and therapeutics across a wide range of conditions, including cancer, rare genetic diseases, and age-related disorders.

"Our goal is to bridge cutting-edge biotechnology with AI to unlock faster and smarter healthcare solutions," said Raul Meza, founder and director of Mendel Biosciences. "We are building a platform that not only supports pharmaceutical companies in their R&D but also empowers doctors, hospitals, and laboratories with smarter diagnostic tools."

The company is currently in its early stages and preparing for a round of fundraising to expand its research team and complete the development of its minimum viable product. The software will be offered through a flexible licensing model targeting pharmaceutical companies, research labs, hospitals, and medical specialists.

Beyond commercial potential, Mendel's work aligns with global priorities in AI and healthcare. Government and institutional support for health innovation and aging research continues to grow, and Mendel aims to contribute meaningfully to the global effort in disease prevention and treatment.

For more information, visit: www.mendelbiosciences.com

Contact Information:

Raul Meza Founder and Director Mendel Biosciences

Email: raul.meza@mendelbiosciences.com

Phone: +52 33 3577 2755

Website: www.mendelbiosciences.com

Media Contact

Mendel Biosciences

********@mendelbiosciences.com

Source: Mendel Biosciences & Pharmaceuticals Mexico

See on IssueWire